BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32036006)

  • 1. Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models.
    Seyedin SN; Hasibuzzaman MM; Pham V; Petronek MS; Callaghan C; Kalen AL; Mapuskar KA; Mott SL; Spitz DR; Allen BG; Caster JM
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):81-92. PubMed ID: 32036006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors.
    Mangoni M; Sottili M; Salvatore G; Meattini I; Desideri I; Greto D; Loi M; Becherini C; Garlatti P; Delli Paoli C; Dominici L; Gerini C; Scoccianti S; Bonomo P; Silvano A; Beltrami G; Campanacci D; Livi L
    Radiat Res; 2018 Nov; 190(5):464-472. PubMed ID: 30067444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
    Calabrese CR; Almassy R; Barton S; Batey MA; Calvert AH; Canan-Koch S; Durkacz BW; Hostomsky Z; Kumpf RA; Kyle S; Li J; Maegley K; Newell DR; Notarianni E; Stratford IJ; Skalitzky D; Thomas HD; Wang LZ; Webber SE; Williams KJ; Curtin NJ
    J Natl Cancer Inst; 2004 Jan; 96(1):56-67. PubMed ID: 14709739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma.
    Wang J; Xing W; Lin Y; Uskenbayeva N; Yan H; Xu Y; Fang L
    J Clin Lab Anal; 2022 May; 36(5):e24435. PubMed ID: 35421273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
    LoRusso PM; Li J; Burger A; Heilbrun LK; Sausville EA; Boerner SA; Smith D; Pilat MJ; Zhang J; Tolaney SM; Cleary JM; Chen AP; Rubinstein L; Boerner JL; Bowditch A; Cai D; Bell T; Wolanski A; Marrero AM; Zhang Y; Ji J; Ferry-Galow K; Kinders RJ; Parchment RE; Shapiro GI
    Clin Cancer Res; 2016 Jul; 22(13):3227-37. PubMed ID: 26842236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts.
    Laird JH; Lok BH; Ma J; Bell A; de Stanchina E; Poirier JT; Rudin CM
    Clin Cancer Res; 2018 Oct; 24(20):5143-5152. PubMed ID: 29945991
    [No Abstract]   [Full Text] [Related]  

  • 8. Veliparib: a new therapeutic option in ovarian cancer?
    Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G
    Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.
    Patel PR; Senyuk V; Rodriguez NS; Oh AL; Bonetti E; Mahmud D; Barosi G; Mahmud N; Rondelli D
    Biol Blood Marrow Transplant; 2019 May; 25(5):855-860. PubMed ID: 30615982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor.
    Krainz T; Lamade AM; Du L; Maskrey TS; Calderon MJ; Watkins SC; Epperly MW; Greenberger JS; Bayır H; Wipf P; Clark RSB
    ACS Chem Biol; 2018 Oct; 13(10):2868-2879. PubMed ID: 30184433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
    Yin L; Liu Y; Peng Y; Peng Y; Yu X; Gao Y; Yuan B; Zhu Q; Cao T; He L; Gong Z; Sun L; Fan X; Li X
    J Exp Clin Cancer Res; 2018 Jul; 37(1):153. PubMed ID: 30012171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.
    Albert JM; Cao C; Kim KW; Willey CD; Geng L; Xiao D; Wang H; Sandler A; Johnson DH; Colevas AD; Low J; Rothenberg ML; Lu B
    Clin Cancer Res; 2007 May; 13(10):3033-42. PubMed ID: 17505006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
    Niu J; Scheuerell C; Mehrotra S; Karan S; Puhalla S; Kiesel BF; Ji J; Chu E; Gopalakrishnan M; Ivaturi V; Gobburu J; Beumer JH
    J Clin Pharmacol; 2017 Aug; 57(8):977-987. PubMed ID: 28387939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells.
    Chiu SJ; Hsaio CH; Tseng HH; Su YH; Shih WL; Lee JW; Chuah JQ
    Biochem Biophys Res Commun; 2010 Apr; 394(3):774-9. PubMed ID: 20227390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
    Thomas HD; Calabrese CR; Batey MA; Canan S; Hostomsky Z; Kyle S; Maegley KA; Newell DR; Skalitzky D; Wang LZ; Webber SE; Curtin NJ
    Mol Cancer Ther; 2007 Mar; 6(3):945-56. PubMed ID: 17363489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.
    Pishvaian MJ; Slack RS; Jiang W; He AR; Hwang JJ; Hankin A; Dorsch-Vogel K; Kukadiya D; Weiner LM; Marshall JL; Brody JR
    Cancer; 2018 Jun; 124(11):2337-2346. PubMed ID: 29579325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer.
    Wang Y; Zheng K; Xiong H; Huang Y; Chen X; Zhou Y; Qin W; Su J; Chen R; Qiu H; Yuan X; Wang Y; Zou Y
    Front Immunol; 2021; 12():762989. PubMed ID: 34975854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for combining immune checkpoint blockade with PARP inhibition.
    Li A; Yi M; Qin S; Chu Q; Luo S; Wu K
    J Hematol Oncol; 2019 Sep; 12(1):98. PubMed ID: 31521196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose) polymerase-1 regulates the mechanism of irradiation-induced CNE-2 human nasopharyngeal carcinoma cell autophagy and inhibition of autophagy contributes to the radiation sensitization of CNE-2 cells.
    Zhou ZR; Zhu XD; Zhao W; Qu S; Su F; Huang ST; Ma JL; Li XY
    Oncol Rep; 2013 Jun; 29(6):2498-506. PubMed ID: 23563481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.